Sign In
Buy IMUX
$13.97
-0.0200 (-0.143%)
At Close: Jul 31, 2026
Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium
08:46am, Tuesday, 24'th Jun 2025
Immunic Inc (NASDAQ:IMUX) released new long-term data from an ongoing study showing that its experimental drug, vidofludimus calcium, continues to help patients with relapsing-remitting multiple scler
– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorabl
Immunic showcases MS drug data at BIO International Convention in Boston - ICYMI
08:01am, Saturday, 21'st Jun 2025
Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio talked with Proactive about the company's participation at the BIO International Convention in Boston and recent clinical developments. T
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted
05:51pm, Monday, 09'th Jun 2025
Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's s
Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMI
09:35am, Saturday, 07'th Jun 2025
Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about the successful completion of patient enrollment for its Phase 3 ENSURE program targeting relapsing mult
Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials
08:32am, Thursday, 05'th Jun 2025
Immunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS). The ENSUR
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial
Immunic raises $65M in public offering to fund clinical trials
04:08pm, Tuesday, 03'rd Jun 2025
Immunic Inc (NASDAQ:IMUX), a biotechnology firm focused on developing oral therapies for chronic inflammatory and autoimmune diseases, on Tuesday closed a previously announced underwritten public offe
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
04:01pm, Tuesday, 03'rd Jun 2025
NEW YORK , June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
Immunic to Participate in Investor, Scientific and Industry Conferences in June
06:30am, Monday, 02'nd Jun 2025
NEW YORK , June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammat
Immunic unveils pricing of $65M underwritten public offering
08:22am, Thursday, 29'th May 2025
Immunic Inc (NASDAQ:IMUX) has announced the pricing of an oversubscribed underwritten public offering that is expected to generate approximately $65 million in gross proceeds, which the company plans
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
07:05am, Thursday, 29'th May 2025
NEW YORK , May 29, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
Immunic, Inc. Announces Proposed Public Offering
04:02pm, Wednesday, 28'th May 2025
NEW YORK , May 28, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
Immunic to Participate in Scientific and Industry Conferences in May
06:30am, Friday, 02'nd May 2025
NEW YORK , May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammato
Immunic reports reduced disability worsening in progressive multiple sclerosis trial
09:36am, Wednesday, 30'th Apr 2025
Immunic Inc (NASDAQ:IMUX) has reported promising results from its Phase 2 CALLIPER trial of vidofludimus calcium, which showed a 30% reduction in the risk of 24-week confirmed disability worsening in
